Invivyd (IVVD) Change in Account Payables (2021 - 2025)
Invivyd's (IVVD) quarterly Change in Account Payables came in at -$4.2 million in Q4 2025, up 41.76% on a YoY basis from -$3.0 million in Q4 2024, and down 1847.71% quarter-over-quarter from -$218000.0 in Q3 2025.
Analysis
Invivyd (IVVD) Change in Account Payables (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has reported Change in Account Payables for 5 consecutive years, with -$4.2 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Change in Account Payables rose 41.76% year-over-year to -$4.2 million; the trailing twelve-month figure through Dec 2025 stood at $3.2 million (up 32.52% YoY), and the FY2025 full-year result was $3.2 million, up 32.52% from the prior year.
- Change in Account Payables eased to -$4.2 million in Q4 2025 per IVVD's latest filing, from -$218000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $12.9 million in Q1 2022 and bottomed at -$14.7 million in Q4 2022.
- Historically, Change in Account Payables has averaged $271750.0 across 5 years, with a median of -$611500.0 in 2021.
- The widest YoY moves for Change in Account Payables: up 443.75% in 2024, down 500.58% in 2024.
- Over 5 years, Change in Account Payables stood at -$11.3 million in 2021, then sank by 30.07% to -$14.7 million in 2022, then soared by 91.73% to -$1.2 million in 2023, then tumbled by 500.58% to -$7.3 million in 2024, then jumped by 41.76% to -$4.2 million in 2025.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$4.2 million, -$218000.0, and $9.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -70.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 18.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -66.70 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -8.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -4.25 Mn |
| Sep 30, 2025 | -218,000.00 |
| Jun 30, 2025 | 9.31 Mn |
| Mar 31, 2025 | -1.64 Mn |
| Dec 31, 2024 | -7.29 Mn |
| Sep 30, 2024 | 10.31 Mn |
| Jun 30, 2024 | 6.19 Mn |
| Mar 31, 2024 | -6.79 Mn |
| Dec 31, 2023 | -1.21 Mn |
| Sep 30, 2023 | 5.06 Mn |
| Jun 30, 2023 | -1.80 Mn |
| Mar 31, 2023 | 4.43 Mn |
| Dec 31, 2022 | -14.67 Mn |
| Sep 30, 2022 | 1.92 Mn |
| Jun 30, 2022 | -4.45 Mn |
| Mar 31, 2022 | 12.90 Mn |
| Dec 31, 2021 | -11.28 Mn |
| Sep 30, 2021 | 6.75 Mn |
| Jun 30, 2021 | -1.01 Mn |
| Mar 31, 2021 | 3.16 Mn |